Top in endocrinology: Hypothyroidism, oral acromegaly capsule

Recent study findings showed a higher prevalence of hypothyroidism in patients with Erdheim-Chester disease, a rare blood cancer. It was the top story in endocrinology last week.

Another top story was about data on the efficacy of an oral formulation of octreotide (Mycapssa, Chiasma) as a long-term maintenance treatment for acromegaly.

Read these and more top stories in endocrinology below:

Higher prevalence of hypothyroidism found in patients with Erdheim-Chester disease

Adults with Erdheim-Chester disease are more likely than those without the disease to have central or primary hypothyroidism and should be screened with a full thyroid panel, according to study findings. Read more.

Oral acromegaly capsule similar to injection therapy in top-line data

An oral form of the somatostatin analogue octreotide was similar to injection therapy as a long-term maintenance treatment for adults with acromegaly, according to top-line data from the MPOWERED trial. Read more.

Glycemic control for pediatric type 1 diabetes improved during Italy’s COVID-19 lockdown

A cohort of children in Italy with type 1 diabetes who used a hybrid closed-loop system had improvement in their glucose levels during the COVID-19 lockdown, according to a research letter published in the Journal of Diabetes. Read more.

No causal link between severe hypoglycemia, increased mortality in type 2 diabetes

Severe hypoglycemic episodes are a marker of, rather than causally related to, an increased risk for death among adults with type 2 diabetes, according to data published in Diabetologia. Read more.

Race disparities persist in CGM use among children with type 1 diabetes

White children with type 1 diabetes are twice as likely to initiate continuous glucose monitoring and four times as likely to persist with therapy at 1 year compared with Black and Hispanic children, regardless of insurance type, data show. Read more.